The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid steady demand across diagnostics and drug-development segments, Labcorp demonstrated significant operational resilience throughout fiscal year 2024. The company reported total revenue of $13.0 billion and operating income of $1.3 billion, achieving an adjusted EPS of $14.57. Furthermore, the firm generated $1.0 billion in free cash flow, of which $679 million was returned to shareholders through dividends and share repurchases.
This performance aligns with broader healthcare sector trends, where peers like Quest Diagnostics also showed stable volume growth; Quest reported 2024 revenues of $9.86 billion per its annual earnings release (Search Citation). According to market data, Labcorp maintained disciplined margins despite inflationary pressures that impacted labor costs across the clinical laboratory industry over the past year.
Labcorp (LH) shares closed at $283.36 (close July 17, 2026), having reached a day high of $290.65. Investors are now monitoring cash flow sustainability in the absence of immediate economic catalysts in the upcoming calendar, focusing on margin stability in future quarters to maintain current support levels above $279.